DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 89

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Summary

This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study aims to determine whether surgery can be safely avoided in patients achieving a complete response, defined by negative endoscopy and tumor-free biopsies after treatment.

Eligibility Criteria

Inclusion and exclusion criteria are identical in both cohorts, except for inclusion criteria 3 and 4. Inclusion criteria The patient is eligible to be included in the study only if all the following criteria apply: 1. Is capable of giving signed and dated informed consent, 2. Has an ECOG PS of 0-1, 3. Age ≥18 years old: * A patient over 70 years of age is eligible to participate in the main initial cohort if the patient respects all the criteria and has a score G8 of ≥14. * A patient over 70 years with a score G8 \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06059495). StuddyBuddy aggregates publicly available trial information.